Now showing items 4-7 of 7

    • KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype 

      Clipson, Alexandra; Wang, Ming; de Leval, Laurence; Ashton-Key, Margaret; Wotherspoon, Andrew; Vassiliou, George; Bolli, Niccolo et al. (Nature Publishing Group, 2014-11-27)
      To characterise the genetics of splenic marginal zone lymphoma (SMZL), we performed whole exome sequencing of 16 cases and identified novel recurrent inactivating mutations in KLF2, a gene whose deficiency was previously ...
    • The Prognosis of MYC Translocation Positive Diffuse Large B-Cell Lymphoma Depends on The Second Hit 

      Clipson, Alexandra; Barrans, Sharon; Zeng, Naiyan; Crouch, Simon; Grigoropoulos, Nicholas F.; Liu, Hongxiang; Kocialkowski, Sylvia et al. (Wiley, 2015-01-08)
      A proportion of MYC translocation positive diffuse large B-cell lymphomas (DLBCL) harbour a BCL2 and/or BCL6 translocation, known as double-hit DLBCL, and are clinically aggressive. It is unknown whether there are other ...
    • Somatic mutation screening using archival formalin-fixed paraffin-embedded tissues by Fluidigm multiplex PCR and Illumina sequencing 

      Wang, Ming; Escudero-Ibarz, Leire; Moody, Sarah; Zeng, Naiyan; Clipson, Alexandra; Huang, Yuanxue; Xue, Xuemin et al. (Elsevier, 2015-07-09)
      High throughput somatic mutation screening using formalin-fixed paraffin-embedded (FFPE) tissues is a major challenge due to a lack of established methodology and validated variant calling algorithms. We aimed to develop ...
    • The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) Trial protocol and baseline cohort characteristics: an open-label pre-test : post-test study with blinded outcome assessments 

      Connick, Peter; Kolappan, Madhan; Patani, Rickie; Scott, Michael A.; Crawley, Charles; He, Xiao-ling; Richardson, Karen et al. (2011-03-02)
      Abstract Background No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the ...